« Back to Farmacia Journal 3/2025

IMPROVEMENT OF NEUROLOGICAL FUNCTION, HEMODYNAMICS, AND ACTIVITIES OF DAILY LIVING IN PATIENTS WITH ISCHEMIC STROKE TREATED WITH TENECTEPLASE INTRAVENOUS THROMBOLYSIS

YAHUI XU, DAQUAN HE, BIN LUO, JING YANG, PEIFU WANG *

Download Full Article PDF

This study assessed the effects of tenecteplase (rh-TNK-TPA) in ischemic stroke treatment, focusing on neurological function, cerebral blood flow, inflammation, and quality of life. Fifty-three patients received rh-TNK-TPA and 47 received alteplase. The rh-TNK-TPA formulation showed a single-chain content of 73.47% and molecular weight of 58,778.23 Da. Baseline data were comparable between groups (p > 0.05). Clinical efficacy was significantly higher in the rh-TNK-TPA group (96.23%) than in the alteplase group (87.23%) (p < 0.05). Neurological biomarkers (NSE, UCH-L1, MBP, GFAP, S-100β) decreased in both groups post-treatment, with more significant reductions in the experimental group. Cerebral blood flow improved, with increased MCA values and decreased ACA/PCA values, more favourable in the rh-TNK-TPA group (p < 0.05). Inflammatory markers, TLR-4, and NF-κB levels declined after treatment, significantly more in the rh-TNK-TPA group (p < 0.05). Quality of life improved in both groups, but more markedly in the experimental group (p < 0.05). Adverse reactions and mortality showed no significant differences (p > 0.05). Overall, rh-TNK-TPA thrombolysis improves clinical outcomes and quality of life by reducing inflammation and neurological injury via TLR-4/NF-κB pathway modulation, supporting its clinical use.